Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
about
New viruses for cancer therapy: meeting clinical needsRetargeting Strategies for Oncolytic Herpes Simplex VirusesOncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyStructure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesionInsertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.Oncolytic viruses: From bench to bedside with a focus on safety.Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Crystal structure of herpes simplex virus 2 gD bound to nectin-1 reveals a conserved mode of receptor recognition.Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD.Directing systemic oncolytic viral delivery to tumors via carrier cellsαvβ6- and αvβ8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion.Fusing structure and function: a structural view of the herpesvirus entry machinery.The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its ReceptorsTargeted entry of enveloped viruses: measles and herpes simplex virus I.Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaSystemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusInhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD.The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1HSV Recombinant Vectors for Gene Therapy.Rethinking herpes simplex virus: the way to oncolytic agents.A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.Retargeting of herpes simplex virus (HSV) vectors.Oncolytic Virotherapy: A Contest between Apples and Oranges.A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection.Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain.Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.Targeting human glioma cells using HSV-1 amplicon peptide display vector.Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.Spotlight on… Gabriella Campadelli-Fiume.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumorsHSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
P2860
Q24567699-83A16999-0AC9-45DE-B735-971FB26A3183Q26765439-C469696C-6559-417B-9CD2-5C61DEF75300Q26998111-5296667E-BA5B-4618-9DF9-0426BFEB067BQ27674775-CD0D179A-1833-46F8-9465-26C9F1743659Q27676007-FF154D64-8C6E-4ADE-A80C-7D06480BF324Q33621028-569AA15D-F6E9-44AF-862F-B94B796ABC37Q33896979-6F1C759D-E24B-4ED5-8301-673F381D4334Q34044071-F22A8FAD-5DD5-472B-821E-C0DC211E747FQ34574879-F727D170-4FF9-4576-86BB-765F76424D5AQ34594121-1C06B82E-265D-4695-AD8E-823E0E1C0CA2Q34613494-483B9FB4-6B42-4B3A-BCBE-395204657FE8Q34621654-BA8ED777-E528-4BB7-97DE-61089E5FE2AAQ34995805-D6AAA396-8911-41B7-8557-B3A83006BFE1Q35029126-7EBD6DB5-48E9-41F9-9849-73B5FC7946E9Q35075118-2BE25856-6F62-4673-81ED-785DAE4DBCAAQ35622700-99941800-5505-4009-937D-7F55568AD955Q35638350-DD47AA6D-4B98-464C-B54B-80B722E95DACQ35851724-F78E0360-8D95-45E4-9D72-65916AB710BBQ35939421-1AACFC8E-E19F-4142-B20B-B82DF2D81AB7Q36544212-8C4E39F4-6C17-4C86-BAC3-A33EA9C2B7F1Q36659325-463F265D-53EE-45D5-928D-069C10210050Q37198935-E54034B5-868E-4071-A3CB-7B4252A7D4DDQ37336556-4B9889C9-D5F7-41D0-BE39-4D3D04524D44Q37459624-C29DC1A1-605B-4E04-9E57-C404172ADEEDQ37691560-9A3FD09E-43AA-4601-BF16-373A03443A8FQ37787777-6EF63136-1AFD-4B82-A95C-EABF4BE71880Q37882608-0F7F76B0-F427-4FC3-A5D4-DB9A0E86CC13Q38714321-FEA4D7A8-C4D3-4E13-AB3D-DAD4721011A2Q38791776-13F2D623-E580-4604-BBC3-38DAAAE0B419Q38950892-E99DFA36-DDC2-4B24-A3EF-84E718B90ECCQ39230055-C396C73C-9A89-4CE0-A4F8-5C8A72595773Q41806893-7EC3CCE0-3D26-4053-9E8A-C16C22731FEAQ42675409-26AE3199-7586-4C59-AF0D-9E8D8B306FBAQ45354666-F2525154-4684-4291-93BA-349C8F466FE1Q45888950-7E4B4EB7-84F1-46A5-B7F9-0942126B2811Q47562626-70B30E91-409F-4A3D-8AD0-C2102571B3B9Q47562637-D41DA09F-6A16-4879-8134-B3C6DD7E8D56Q54968880-572C4F69-272B-4B0F-8501-3254D8E66191Q56348401-E7D0B22C-F3B4-4DC6-9C77-59E26145571FQ56378150-A5C33952-06F3-4D8C-95F5-7F7244EEE87E
P2860
Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Construction of a fully retarg ...... rmal growth factor receptor 2.
@en
Construction of a fully retarg ...... rmal growth factor receptor 2.
@nl
type
label
Construction of a fully retarg ...... rmal growth factor receptor 2.
@en
Construction of a fully retarg ...... rmal growth factor receptor 2.
@nl
prefLabel
Construction of a fully retarg ...... rmal growth factor receptor 2.
@en
Construction of a fully retarg ...... rmal growth factor receptor 2.
@nl
P2093
P2860
P356
P1433
P1476
Construction of a fully retarg ...... rmal growth factor receptor 2.
@en
P2093
Arianna Cerretani
Hartmut Hengel
Laura Menotti
P2860
P304
10153-10161
P356
10.1128/JVI.01133-08
P407
P577
2008-08-06T00:00:00Z